1. 1959. Ceftriaxone-Sulbactam-EDTA (CSE) vs. Meropenem (MR) in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes in Patients Infected With Ceftriaxone Non-Susceptible, Extended-Spectrum β-Lactamase and Multi-Drug-resistant Pathogens at Baseline. (26th November 2018) Authors: Mir, Mohd Amin; Chaudhary, Saransh; Mammen, Kim Jacob; Sood, Rajeev; Dogra, P N; Chadha, Sudhir; Mavuduru, Ravimohan; Sinha, Rahul Janak; Chaudhary, Manu; Shiekh, Gazalla Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S567 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗